Results 201 to 210 of about 27,163 (253)

Pediatric-Onset Multiple Sclerosis in Tyrol, Austria: Epidemiology, Clinical Profile and Treatment Patterns from a Single Center (2015-2024). [PDF]

Children (Basel)
Lechner C, Schoedl C, Breu M, Peternell A, Baumann M.   +4 more
europepmc   +1 more source

An atypical presentation of immune reconstitution inflammatory syndrome (IRIS) in a patient with cryptococcal meningitis in the setting of fingolimod therapy for multiple sclerosis. [PDF]

IDCases
Nel H, Hui S.
europepmc   +1 more source

Activation of sphingosine-1-phosphate receptors can relieve myocardial ischemia-reperfusion injury by mitigating oxidative stress and ferroptosis in cardiomyocytes. [PDF]

Int J Biol Sci
Xu X, Li R, Li S, Wei Q, Yu F, Ma G, Tong J.   +6 more
europepmc   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Ann Clin Transl Neurol
Shahzad F, Rasheed T, Siddiqui MR, Hamid H, Khalid MB, Shabbir H, Shami B, Abdullah, Ahmed SI.   +8 more
europepmc   +1 more source

Imaging and targeting S1PR1 in HER2+ tumors. [PDF]

Nucl Med Biol
Shmuel S, Qiu L, Vanover A, Chen H, Jiang H, Tu Z, Pereira PMR.   +6 more
europepmc   +1 more source

Therapeutic effects of fingolimod through sphingosine-1-phosphate signaling in pulmonary arterial hypertension

Moe Fujiwara, Aya Yamamura, Rubii Kondo, Yoshiaki Suzuki, Hisao Yamamura   +4 more
openalex   +1 more source

Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment? [PDF]

Curr Issues Mol Biol
Baloglu M, Vejselova Sezer C, Izgördü H, Yilmaz I, Kutlu HM.   +4 more
europepmc   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod. [PDF]

Front Pharmacol
Wu Y, Ke W, Li H.
europepmc   +1 more source